1. Home
  2. ETNB vs DK Comparison

ETNB vs DK Comparison

Compare ETNB & DK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • DK
  • Stock Information
  • Founded
  • ETNB 2018
  • DK 2001
  • Country
  • ETNB United States
  • DK United States
  • Employees
  • ETNB N/A
  • DK N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • DK Integrated oil Companies
  • Sector
  • ETNB Health Care
  • DK Energy
  • Exchange
  • ETNB Nasdaq
  • DK Nasdaq
  • Market Cap
  • ETNB 1.5B
  • DK 1.6B
  • IPO Year
  • ETNB 2019
  • DK 2006
  • Fundamental
  • Price
  • ETNB $8.87
  • DK $31.32
  • Analyst Decision
  • ETNB Strong Buy
  • DK Hold
  • Analyst Count
  • ETNB 10
  • DK 12
  • Target Price
  • ETNB $27.22
  • DK $24.50
  • AVG Volume (30 Days)
  • ETNB 1.5M
  • DK 2.4M
  • Earning Date
  • ETNB 11-06-2025
  • DK 11-05-2025
  • Dividend Yield
  • ETNB N/A
  • DK 3.26%
  • EPS Growth
  • ETNB N/A
  • DK N/A
  • EPS
  • ETNB N/A
  • DK N/A
  • Revenue
  • ETNB N/A
  • DK $10,822,600,000.00
  • Revenue This Year
  • ETNB N/A
  • DK N/A
  • Revenue Next Year
  • ETNB N/A
  • DK N/A
  • P/E Ratio
  • ETNB N/A
  • DK N/A
  • Revenue Growth
  • ETNB N/A
  • DK N/A
  • 52 Week Low
  • ETNB $4.16
  • DK $11.03
  • 52 Week High
  • ETNB $11.84
  • DK $32.48
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 43.45
  • DK 74.43
  • Support Level
  • ETNB $8.46
  • DK $21.09
  • Resistance Level
  • ETNB $9.47
  • DK $32.48
  • Average True Range (ATR)
  • ETNB 0.46
  • DK 1.65
  • MACD
  • ETNB -0.02
  • DK 0.87
  • Stochastic Oscillator
  • ETNB 33.33
  • DK 89.82

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About DK Delek US Holdings Inc.

Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has two segments: Refining segment and Logistics segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.

Share on Social Networks: